CircRNA (circ)_0007823 Contributes to Triple-Negative Breast Cancer Progression and Cisplatin Resistance via the miR-182-5p/FOXO1 Pathway-Reference-Cited by-同舟云学术

CircRNA (circ)_0007823 Contributes to Triple-Negative Breast Cancer Progression and Cisplatin Resistance via the miR-182-5p/FOXO1 Pathway

Published:2024-04-01 Issue: Volume: Page:
ISSN:0006-2928
Container-title:Biochemical Genetics
language:en
Short-container-title:Biochem Genet

Author:

Wang Haofeng,Wang Xiaojie,Shen Weida,Zhou Yingzi,Cui Jing,Li Haichuan,Yu Jinling

Funder

Changning Maternity and Infant Health Hospital

Shanghai Municipal Health Commission

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10528-024-10783-9.pdf

Reference31 articles.

1. Ali Salman RJC, Molecular, Reports B (2023) Prevalence of women breast cancer. 3(4):185–196. https://doi.org/10.55705/cmbr.2023.384467.1095

2. Anilkumar KV et al (2023) miRNAs in the prognosis of triple-negative breast cancer: a review. Life Sci 333:122183

3. Cao M-Q et al (2018) Mir-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol 11(1):12

4. Chen J et al (2022) CircRNA_0044556 diminishes the sensitivity of triple–negative breast cancer cells to adriamycin by sponging miR–145 and regulating NRAS. Mol Med Rep 25(2):1–12

5. Coffetti G et al (2023) The challenging treatment of cisplatin-resistant tumors: state of the art and future perspectives. Molecules 28(8):3407

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer;Cancer Drug Resistance;2024-08-19

2. MicroRNA-based interventions in aberrant cell cycle diseases: Therapeutic strategies for cancers, central nervous system disorders and comorbidities;Biomedicine & Pharmacotherapy;2024-08